DISCLAIMER
This is not a solicitation for securities
The material in this presentation has been prepared by Science 37 and
is general background information about Science 37s activities current
as at the date of this presentation. This information is given in summary
form and does not purport to be complete. Information in this
presentation, including forecast financial information, should not be
considered as advice or a recommendation to investors or potential
investors in relation to holding, purchasing or selling securities or other
financial products or instruments and does not take into account your
particular investment objectives, financial situation or needs. Before
acting on any information you should consider the appropriateness of
the information having regard to these matters, any relevant offer
document and in particular, you should seek independent financial
advice.
All securities and financial product or instrument transactions involve
risks, which include (among others) the risk of adverse or unanticipated
market, financial or political developments and, in international
transactions, currency risk. This presentation may contain forward
looking statements including statements regarding our intent, belief or
current expectations with respect to Science 37s businesses and
operations, market conditions, results of operation and financial
condition, capital adequacy, specific provisions and risk management
practices. Readers are cautioned not to place undue reliance on these
forward looking statements. Science 37 does not undertake any
obligation to publicly release the result of any revisions to these
forward looking statements to reflect events or circumstances after the
date hereof to reflect the occurrence of unanticipated events. While
due care has been used in the preparation of forecast information,
actual results may vary in a materially positive or negative manner.
Forecasts and hypothetical examples are subject to uncertainty and
contingencies outside Science 37s control.
THE PROBLEM
Scientific discoveries take too long to get to market.

Clinical trials can take several years before a technology

is even brought to market. In many cases, this can be
accelerated with greater collaboration within the
medical community.

According to a research by the US Department of Health, clinical trials take an average of eight years to pass from the time a drug enters clinical trials
to the point it receives approval from regulatory agencies for sale to the public. For biotechnology researchers, this means an extensive amount of
expenditures are received with little or no income. For patients, this means that they could receive access to life saving drugs before its too late.

3
CLINICAL TRIAL PROBLEM
Phase III clinical trails is slowing the time to market for many drugs and hurting biotechnology companies

Over the past decade, several scientific discoveries

have been made, but this only scratches the surface 90%
of the potential ones. Millions of people are suffering
from diseases that may die before the treatment is
being released onto the market due to being held-up
during clinical trials.
70%
There are hundreds of thousands of drugs that enter
the clinical trail phase pipeline each year, almost all of
which could be expedited in some way by using
45%
Science 37. The data from clinical trail applications 40%
shows that nearly all drugs could have been
accelerated in some way by. 25%

2011

2013
2010

2012

2014
Of Phase III drugs Of Phase III drugs Of Phase III drugs Of Phase III drugs Of Phase III drugs
could have reached could have reached could have reached could have reached could have reached
the market sooner the market sooner the market sooner the market sooner the market sooner

4
OUR SOLUTION
Using mobile technology and the scientific community to accelerate clinical trials

Science 37 combines mobile technology with clinical trial

development to accelerate the clinical trials process by
collaborating with other professionals in the medial
community with a mobile application linked to a social
network.

It is the first business of its kind to connect tens of thousands

of healthcare professionals and allow them to help bring life
saving drugs to the market faster and ensure that they safely
are approved by regulatory agencies.

HEALTHCARE NETWORK
Access to every healthcare professional through a
mobile application contributing.

REDUCE PHASE III DRUG TIME

Results in reduced clinical trial phase testing and
helps life saving drugs enter the market sooner.

5
MISSION & TARGET
We aim to decrease the time required for clinical trial stage testing

There are four main factors that we are focusing on in our value proposition to help accelerate the launch time of life saving drugs through professional collaboration, sharing of data, a
worldwide network, and regulatory oversight that will help to save millions of lives and contribute to a more efficient biotechnology industry.

REDUCED CLINICAL TRAIL TIME

The primary goal is to reduce the amount of time
that drugs spend in Phase III of clinical trials.

DATA & INFORMATION SHARING

The application will increase the organization and
storage of critical information about results.

INTERNATIONAL COLLABORATIOn
Medical professionals worldwide can assist with
helping the life saving drugs enter the market.

REGULATORY OVERSIGHT
Regulators have access to all data and results in an
organized manner to keep consumers protected.

6
OUR RESULTS
A proven ability to reduce clinical trial testing time

total
According to our research findings, drugs that enter Phase III,
clinical trails using S 37 are 98% more likely to have a faster
98%
approval process. Drugs that did not have any interaction
with S 37 at all were 35% more likely to have a slower total
approval process. The percentages ranged based upon the
drug classification, but overall demonstrate that the platform 35%
can rapidly increase the time to market.

BEFORE S37 AFTER S37

Drugs spent in the The drugs using S37 were
clinical trial phase testing reduced by a total of
took 35% longer. 98% in Phase III.

Anti-Biotics A.C.E. Inhibitors Drugs 9%

Drugs that are used to treat design to inhibit ACE. 10%
bacterial infections. 21%
18%
23%
Anti-Convulsants- Drugs Benzodiazepines - Drugs 15%
58%
used to prevent and treat used to treat anxiety and 46%
seizures and convulsions. other related symptoms.

7
AN EXPERIENCED
MANAGEMENT TEAM
TO STAY AHEAD
OF THE COMPETITION
Meet Our Team Members

Bill Williams Jun Ke Lee Ben Franks Ankit Kapur

Founder/CEO Founder/COO Compliance Marketing Director
Meet Our Advisory Board

Hamad Kapur Mike Green Emily Miller

Biotechnology Business Development Engineering
BUSINESS MODEL
How we help to accelerate the clinical trial approval and generate profits
 MOBILE APPLICATION
A simple, yet efficient solution to network all professionals for Phase III

The S37 mobile application is a simple, yet highly efficient solution to network hundreds of
thousands of doctors around the world onto a single platform to collaborate on desktop or mobile
devices for clinical trial phase testing to ensure faster and more reliable results.

75% 45% 85%

FASTER DELIVERY MORE EFFICIENT BETTER RESULTS

The time spent in Phase III is Collaboration among The outcomes of the clinical
reduced by nearly 75% healthcare professionals is trails are 85% more reliable
through the mobile app increased by 45% with the extended reach

12
CORE VALUE
Accelerated clinical trial approval procedure

There are many proposed solutions on the market design to

accelerate the clinical trail process, but most of these
solutions presently focus on the internal resources that a
biotechnology company has at its disposal and very few
options source solutions from outside the company.
FEEDBACK
Many companies are resistant to engage with outside parties Ongoing communication among
as it may disclose pertinent and confidential information scientific and healthcare
regarding the nature of the business model or formula. TESTING
professionals for improvement.
However, S 37 collaborates with third-parities in a Testing feedback and
confidential manner that protects the patents and formulas communication during the
from the biotechnology companies in the clinical trail phase . clinical trail process.

APPROVAL ACCELERATION
Greater collaboration and An accelerated clinical trail
communication results in a process means faster drugs to
higher rate of approval. market.

13
BUSINESS MODEL
The sequence of actions of how people relate to S 37

RESEARCH
01 The research phase is completed internally from
customers before they engage with the platform. RESEARCH

DESIGN
02 The design stage is done at the beginning of clinical
trials regarding how it will be structured. DELIVER
S 37 DESIGN
TEST PROCESS
03 The testing of clinical trails is the main point at
which people engage with the S 37 platform.

MODIFY
04 Any modifications to the drug are made in order to
reach FDA approval for commercialization.
MODIFY
TEST
DELIVER
05 The drug is approved by the FDA, passes Phase III
clinical trials and enters the market.

14
SWOT ANALYSIS
An analysis of our business model and how we intend to transform the clinical trail market

There are several weaknesses and threats that S 37 will encounter, but through efficient testing and analysis, the company can overcome these and grow to become the leading authority
on the market for clinical trail testing. The following analysis provides information regarding how S 37 will saturate the market for clinical trails testing.

STRENGTHS WEAKNESSES
Proven demand for the product. Need more international expansion, but working on

An existing social network and user base.

Applicability over all drug testing classifications.
Receptive market to participate outside the company.
Ability to protect privacy and formulas.
S W
growing in other counties to combat this.
Potential that other similar platforms could enter the
market, which increases importance to quickly grow.

OPPORTUNITIES THREATS
The clinical trial phase currently takes an average of Some companies can perceive communication with any

eight years and many companies cannot last that long.

Companies have incurred substantial expenses waiting
to complete the Phase III clinical trails.
O T outside parties as risky, but the platform protects
patents and formulas to ensure that communication
does not result in infringement.

15
 OUR HISTORICAL
AND PROJECTED
PERFORMANCE
FOR THE NEXT THREE YEARS.
RECENT ACHIEVEMENTS
Our current accomplishments on the platform to date

The development of our platform has quickly grown from our

launch in 2015 to raise over $60 M and reach over 200,000
professional enterprise users with a presence in Germany,
United States, London, and Israel. The platform continues to 2017
grow substantially each quarter. Raise $29 M by
seven investors
The application recently also received regulatory approval to
be used during Phase III testing as a means for healthcare and
biotechnology professionals to collaborate on the
development of new drugs as a way to receive feedback and
third-party information.
Q4 2016
Receive approval
for the app by
regulators

Q4 2015
Q3 2016 Series A round
Raise $31 m in raised to develop
series B round platform

Q1 2016
Increase to over
200,000 users

17
HISTORICAL METRICS
An overview of our performance to date from users, Phase III drugs, and revenue

90

80

70

60
Millions

Drugs
50
Revenue
40 Profit
30 Users

20

10

0
3/1/2016 4/1/2016 5/1/2016 6/1/2016 7/1/2016 8/1/2016

The platform has continued to grow at impressive rates with both new users uploading Phase III drugs, along with more experts contributing to testing and approval on the application.
The revenue has increased relative to the amount of new users and drugs on the platform with profit increasing relative to revenue and the extent of research & development invested
into the platform. The financial projections (appended) assume an extrapolation of the historical growth over the next three years.

18
SOCIAL NETWORK
Create, share or exchange information and ideas
1.14
million
There is a growing network of healthcare
professionals using S 37 internationally with the
largest presence in the United States, Australia, and
Germany. These three countries serve as regional
hubs to further expand throughout the Americas,
Oceana, and Western Europe.

Moreover, further investments will be made into the

platforms that S 37 is accessible on to accommodate
all technology usage preferences.
1.46
127 million

million

THE CURRENT USER STATE OF ACCESS TO

S 37 BY PLATFORM AND USAGE BEHAVIOR 0.7 M 0.5 M 1.4 M 0.9 M
OVER THE PAST TWO YEARS

Nearly one million users One half million users are Most users are accessing Second to mobile phones,
are operating on the accessing the platform the application through users are accessing the
desktop version. from a laptop device. an Android or iOS device. platform using a tablet.

19
GROWTH BY SEGMENT ($ M)
An analysis of growth by user segment and drug classification

75% 38% 60% 90%

$806,700 $460,000 $620,500 $1,200,000

Total Sales: 300,000 Total Sales: 200,000 Total Sales: 250,000 Total Sales: 990,000

Experimental drugs that have Drugs that are considered low Drugs that treat well Drugs that have a short Phase
a high chance of not receiving to moderate risk and have recognized diseases but still III process and are shortlisted
approval from FDA limited marketability have a limited approval rate through clinical trails

20
FINANCIAL
PROJECTIONS
AND
CURRENT FUNDRAISING
Fundraising Round ($ M)
The proposed use of funds for the current fundraising round

The following provides a list of the current breakdown of expenses for the existing fundraising round by category. The majority of expenses are needed for ongoing research &
development for the platform, with an addition amount needed for cash on hand to cover operating expenses until the business has enough substance to generate a profit.

Funding Expenses Liabilities

Legal Fees 25,000 Liabilities and Capital
Research & Development 300,000 Current Borrowing -
Employee Expenses 16,000 Long-Term Liabilities -
Business Development 170,000 Accounts Payable -
Misc. SG&A 25,000 Other Current Liabilities -
Total Startup Expenses $536,000

Funding Assets Equity Investments

Cash on Hand 3,412,000 Planned Investment
Total Startup Assets $3,412,000 Owner 100,000
Investor 3,900,000
Total Requirements Total Planned Investment $4,000,000
Total Startup Expenses $536,000
Total Startup Assets 3,412,000
Round Funding
Total Requirements $3,948,000 Total Liabilities -
Total Planned Investment 4,000,000
Total Funding $4,000,000

22
Three Year Financial Highlights ($ M)
A brief analysis of the financial projections (full model available upon request)

Projected Operating Highlights By Year ($000,000) Projected Revenues By Year ($000,000)

3000 3000
Revenue
2500 2500
2000 Gross Margin 2000
1500 1500
1000 EBITDA 1000
500 500
Net Profit
0 0
(500) Year 1 Year 2 Year 3 Year 1 Year 2 Year 3

Projected Cash Flow By Year ($000,000) Projected Net Income By Year ($000,000)
5000 800
4000 600
Net Cash Flow
3000
400
2000
200
1000 Cash Balance
0
0
Year 1 Year 2 Year 3
Year 1 Year 2 Year 3 (200)

23
 12 Month Revenue Projections ($ M)
A brief analysis of the financial projections (full model available upon request)

Year 1 Revenue Monthly ($000) Revenue By Year ($000)

90,000 3000
80,000
70,000 2500

60,000
2000
50,000
40,000
1500
30,000
20,000 1000
10,000
- 500
Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12 0
Year 1 Year 2 Year 3

24
 Three Year Financial Highlights ($ M)
A brief analysis of the financial projections (full model available upon request)

Financial Highlights ($000,000)

Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 Year 1 Year 2 Year 3
Revenue 71 71 54 55 61 62 63 65 67 70 74 80 793 1523 2590
Gross Margin 54 54 41 41 46 47 47 49 50 53 55 60 595 1142 1942
Operating Expense 28 28 28 28 28 28 28 28 28 28 28 28 332 531 867
EBITDA 12 12 (1) (1) 4 5 5 7 8 11 13 18 92 390 787
Net Profit (3) (3) (16) (15) (11) (10) (9) (8) (6) (4) (1) 4 (81) 217 614

Gross Margin/Revenue 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75%
EBITDA/Revenue 16% 16% -3% -1% 6% 7% 9% 11% 12% 15% 18% 23% 12% 26% 30%
Net Profit/Revenue -4% -4% -29% -27% -17% -16% -14% -12% -9% -5% -2% 5% -10% 14% 24%

Net Cash Flow 12 12 (1) (1) 4 5 5 7 8 11 13 18 92 390 787

Cash Balance - Ending 537 548 547 546 550 555 560 567 575 586 599 617 617 1007 1795

25
Three Year Profit & Loss ($ M)
A brief analysis of the financial projections (full model available upon request)

Pro Forma Profit and Loss ($000)

Year 1 Year 2 Year 3
Revenue $ 793,357 $ 1,523,246 $ 2,589,518
Subtotal Cost of Revenue $ 198,339 $ 380,811 $ 647,379
Total Cost of Revenue $ 198,339 $ 380,811 $ 647,379

Gross Margin $ 595,018 $ 1,142,434 $ 1,942,138

Gross Margin/Revenue 75% 75% 75%

Expenses
Public Relations & Marketing 300,000 456,974 776,855
Tradeshows 7,200 20,800 20,800
Banking Fees 420 21,200 27,560
Office Expenses & Utilities 2,400 3,120 4,056
Travel & Communication 3,600 4,680 6,084
Misc. SG&A 9 24,149 31,393
Total Operating Expenses $ 313,629 $ 530,923 $ 866,749

Wages & Payroll $ 170,511 $ 221,591 $ 287,995

Depreciation, Amortization & Taxes $ 173,333 $ 173,333 $ 173,333
Net Income $ (81,023) $ 216,587 $ 614,061
Net Income/Revenue -10% 14% 24%

26
 12 Month Profit & Loss ($ M)
A brief analysis of the financial projections (full model available upon request)

Year 1 Profit & Loss ($000)

Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Revenue 71,429 71,429 54,000 55,000 61,000 62,000 63,000 65,000 67,000 70,000 73,500 80,000
Subtotal Cost of Revenue 17,857 17,857 13,500 13,750 15,250 15,500 15,750 16,250 16,750 17,500 18,375 20,000
Total Cost of Revenue 17,857 17,857 13,500 13,750 15,250 15,500 15,750 16,250 16,750 17,500 18,375 20,000

Gross Margin $ 53,571 $ 53,571 $ 40,500 $ 41,250 $ 45,750 $ 46,500 $ 47,250 $ 48,750 $ 50,250 $ 52,500 $ 55,125 $ 60,000
Gross Margin/Revenue 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75%

Expenses
Public Relations & Marketing 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000
Tradeshows 600 600 600 600 600 600 600 600 600 600 600 600
Banking Fees 35 35 35 35 35 35 35 35 35 35 35 35
Office Expenses & Utilities 200 200 200 200 200 200 200 200 200 200 200 200
Travel & Communication 300 300 300 300 300 300 300 300 300 300 300 300
Misc. SG&A 1,548 1,548 1,548 1,548 1,548 1,548 1,548 1,548 1,548 1,548 1,548 1,548
Total Operating Expenses $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683 $ 27,683

EBIT $ 25,888 $ 25,888 $ 12,817 $ 13,567 $ 18,067 $ 18,817 $ 19,567 $ 21,067 $ 22,567 $ 24,817 $ 27,442 $ 32,317
EBIT/Revenue 36% 36% 24% 25% 30% 30% 31% 32% 34% 35% 37% 40%

27
Feel Free To Send Us A
Message Or Call
12121 Bluff Creek Dr #100, Los Angeles, CA 90094

(984) 377-3737

info@science37.com

https://www.facebook.com/Science37

@Science_37